Inhibition of platelet aggregation by clopidogrel sulfate: Dose-finding clinical pharmacology study:Dose-finding clinical pharmacoloy study
スポンサーリンク
概要
- 論文の詳細を見る
Platelet aggregation is triggered by the activation of GPIIb/IIIa and binding of fibrinogen, which are induced by the ADP released from damaged vessels and red blood cells. Clopidogrel sulfate (SR25990C, clopidogrel) is an oral antiplatelet agent containing a thienopyridine ring within its structure, and its antiplatelet effect is based on its inhibitory action towards ADP receptor. The present double-blind controlled clinical pharmacology study was performed on 124 Japanese patients with cerebral infarction, who were given 10, 37.5, or 75mg/day of clopidogrel for 2 weeks in order to evaluate the relationship between dose of clopidogrel and inhibition of platelet aggregation. In addition, ticlopidine (200 mg/day) was administered to a positive control group. The percent inhibition of platelet aggregation with ticlopidine was 34.9%, and that with 10, 37.5, and 75 mg/day of clopidogrel was 14.0, 26.6, and 39.8%, respectively. On the basis of these results, the recommended clinical dose of clopidogrel for Japanese patients with cerebral infarction was concluded to be 75mg/day.
- 一般社団法人 日本脳卒中学会の論文
一般社団法人 日本脳卒中学会 | 論文
- Two cases with aphasia in the left putaminal damage and one case with visuospatial neglect in the right putaminal damage
- Alterations of plasma von Willebrand factor activity and the influence of anti-platelet drugs in acute cerebral infarction
- Carotid endarterectomy plaques correlation of clinical events and morphology.
- Stenting for stenosis of major cerebrovascular arteries.
- Cerebral infarction following antihypertensive therapy.